Overview
Employees
11-50
Total raised
$2.4M
Founded date
2012
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 2, 2023 | Zurich-based Memo Therapeutics secures €26 million Series C to speed up clinical development for renal transplant patients | |
| Nov 2, 2023 | Memo Therapeutics secures CHF 25 million series C to speed up clinical development for renal transplant patients | Memo Therapeutics secures CHF 25 million series C to speed up clinical development for renal transplant patients 02.11.2023 10:49, Rita Longobardi linkedIn facebook twitter instagram youtube --> The funding will be crucial in advancing M... |
| Jun 13, 2018 | New CEO and CMO for biotech startups | |
| May 9, 2018 | CHF 5 million for Memo Therapeutics | |
| May 9, 2018 | Memo Therapeutics Closes CHF5.0M Series A2 Financing Round | Memo Therapeutics AG, a Basel, Switzerland-based innovator in the field of antibody discovery and human immune repertoire analysis, closed a CHF 5.0m Series A2 financing round. The round included new investors Schroder Adveq, investiere.ch ... |
| May 23, 2017 | Memo Therapeutics announces proof of concept of its antibody platform | |
| Mar 17, 2017 | Great interest in the redesigned Swiss Venture Day | |
| Nov 23, 2016 | Memo Therapeutics completes first commercial project | |
| Jul 23, 2015 | Memo Therapeutics Closes CHF2.3M Series A Financing | Memo Therapeutics, a Basel/Zurich-based developer of a platform technology for antibody discovery, closed a CHF2.3m Series A financing. The round by Redalpine and other Swiss investors, including EVA Basel and Zürcher Kantonalbank. The comp... |
Show more
Reviews 0
FAQ about MemoMab
When was MemoMab founded?
MemoMab was founded in 2012.
How much funding has MemoMab raised?
MemoMab has raised $2.4M in total across 1 funding round.
What has the press written about MemoMab?
Parsers VC has collected 11 articles mentioning MemoMab, among them “Zurich-based Memo Therapeutics secures €26 million Series C to speed up clinical development for renal transplant patients” (Nov 2, 2023) and “Memo Therapeutics secures CHF 25 million series C to speed up clinical development for renal transplant patients” (Nov 2, 2023).
Is MemoMab still active?
Yes, MemoMab is active; its latest activity on Parsers VC dates from May 7, 2024.